4528:TYO
Ono Pharmaceutical Co Ltd
2 257,50 JPY
arrow_downward
−0,73%(−16,50) 1 d
7 okt., 15:30:00 GMT+9 · JPY
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för 4528 …
Öppen
2 262 JPY
Högt
2 286 JPY
Lågt
2 258 JPY
Börsvärde
1,13 bn
Genomsn. vol.
1,44 mn
Volym
1,96 mn
Utdelning
3,54 %
Kvartalsvis utdelning
20 JPY
Ex-utdelningsdatum
29 sep. 2026
P/E-tal
13,92
52v högst
2 674 JPY
52v lägst
1 703 JPY
EPS
162 JPY
Utestående aktier
514,12 mn
Antal anställda
4 tn
Öppen
2 262 JPY
Högt
2 286 JPY
Lågt
2 258 JPY
Börsvärde
1,13 bn
Genomsn. vol.
1,44 mn
Volym
1,96 mn
Utdelning
3,54 %
Kvartalsvis utdelning
20 JPY
Ex-utdelningsdatum
29 sep. 2026
P/E-tal
13,92
52v högst
2 674 JPY
52v lägst
1 703 JPY
EPS
162 JPY
Utestående aktier
514,12 mn
Antal anställda
4 tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
TipRanks
·
för 15 timmar sedan
Ono’s New Pediatric Cancer Trial Signals Steady Pipeline Progress for O.P.H.L.F Investors
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Om Ono Pharmaceutical Co Ltd
VdGyo Sagara | Gyo Sagara
Anställda4,21 tn
Grundades1717
HuvudkontorOsaka, Osaka prefektur, Japan
Sektor-
Webbplatsono-pharma.com